Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1.
Alternative splicing
Breast cancer
P-AKT-C-MYC
PTPMT1
SRSF1
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
15 May 2021
15 May 2021
Historique:
received:
23
12
2020
accepted:
09
05
2021
entrez:
16
5
2021
pubmed:
17
5
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Intensive evidence has highlighted the effect of aberrant alternative splicing (AS) events on cancer progression when triggered by dysregulation of the SR protein family. Nonetheless, the underlying mechanism in breast cancer (BRCA) remains elusive. Here we sought to explore the molecular function of SRSF1 and identify the key AS events regulated by SRSF1 in BRCA. We conducted a comprehensive analysis of the expression and clinical correlation of SRSF1 in BRCA based on the TCGA dataset, Metabric database and clinical tissue samples. Functional analysis of SRSF1 in BRCA was conducted in vitro and in vivo. SRSF1-mediated AS events and their binding motifs were identified by RNA-seq, RNA immunoprecipitation-PCR (RIP-PCR) and in vivo crosslinking followed by immunoprecipitation (CLIP), which was further validated by the minigene reporter assay. PTPMT1 exon 3 (E3) AS was identified to partially mediate the oncogenic role of SRSF1 by the P-AKT/C-MYC axis. Finally, the expression and clinical significance of these AS events were validated in clinical samples and using the TCGA database. SRSF1 expression was consistently upregulated in BRCA samples, positively associated with tumor grade and the Ki-67 index, and correlated with poor prognosis in a hormone receptor-positive (HR+) cohort, which facilitated proliferation, cell migration and inhibited apoptosis in vitro and in vivo. We identified SRSF1-mediated AS events and discovered the SRSF1 binding motif in the regulation of splice switching of PTPMT1. Furthermore, PTPMT1 splice switching was regulated by SRSF1 by binding directly to its motif in E3 which partially mediated the oncogenic role of SRSF1 by the AKT/C-MYC axis. Additionally, PTPMT1 splice switching was validated in tissue samples of BRCA patients and using the TCGA database. The high-risk group, identified by AS of PTPMT1 and expression of SRSF1, possessed poorer prognosis in the stage I/II TCGA BRCA cohort. SRSF1 exerts oncogenic roles in BRCA partially by regulating the AS of PTPMT1, which could be a therapeutic target candidate in BRCA and a prognostic factor in HR+ BRCA patient.
Sections du résumé
BACKGROUND
BACKGROUND
Intensive evidence has highlighted the effect of aberrant alternative splicing (AS) events on cancer progression when triggered by dysregulation of the SR protein family. Nonetheless, the underlying mechanism in breast cancer (BRCA) remains elusive. Here we sought to explore the molecular function of SRSF1 and identify the key AS events regulated by SRSF1 in BRCA.
METHODS
METHODS
We conducted a comprehensive analysis of the expression and clinical correlation of SRSF1 in BRCA based on the TCGA dataset, Metabric database and clinical tissue samples. Functional analysis of SRSF1 in BRCA was conducted in vitro and in vivo. SRSF1-mediated AS events and their binding motifs were identified by RNA-seq, RNA immunoprecipitation-PCR (RIP-PCR) and in vivo crosslinking followed by immunoprecipitation (CLIP), which was further validated by the minigene reporter assay. PTPMT1 exon 3 (E3) AS was identified to partially mediate the oncogenic role of SRSF1 by the P-AKT/C-MYC axis. Finally, the expression and clinical significance of these AS events were validated in clinical samples and using the TCGA database.
RESULTS
RESULTS
SRSF1 expression was consistently upregulated in BRCA samples, positively associated with tumor grade and the Ki-67 index, and correlated with poor prognosis in a hormone receptor-positive (HR+) cohort, which facilitated proliferation, cell migration and inhibited apoptosis in vitro and in vivo. We identified SRSF1-mediated AS events and discovered the SRSF1 binding motif in the regulation of splice switching of PTPMT1. Furthermore, PTPMT1 splice switching was regulated by SRSF1 by binding directly to its motif in E3 which partially mediated the oncogenic role of SRSF1 by the AKT/C-MYC axis. Additionally, PTPMT1 splice switching was validated in tissue samples of BRCA patients and using the TCGA database. The high-risk group, identified by AS of PTPMT1 and expression of SRSF1, possessed poorer prognosis in the stage I/II TCGA BRCA cohort.
CONCLUSIONS
CONCLUSIONS
SRSF1 exerts oncogenic roles in BRCA partially by regulating the AS of PTPMT1, which could be a therapeutic target candidate in BRCA and a prognostic factor in HR+ BRCA patient.
Identifiants
pubmed: 33992102
doi: 10.1186/s13046-021-01978-8
pii: 10.1186/s13046-021-01978-8
pmc: PMC8122567
doi:
Substances chimiques
SRSF1 protein, human
0
Serine-Arginine Splicing Factors
170974-22-8
Ptpmt1 protein, human
EC 3.1.3.-
PTEN Phosphohydrolase
EC 3.1.3.67
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Subventions
Organisme : Excellent Backbone Plan of Zhongshan Hospital in 2019
ID : 2019ZSGG08
Organisme : National Natural Science Fund of China
ID : 81871916; 82072670; 81672330
Organisme : National Natural Science Fund of China
ID : 82072908
Références
Int J Biochem Cell Biol. 2019 Aug;113:75-86
pubmed: 31200124
RNA. 2013 Jan;19(1):96-102
pubmed: 23175589
Mol Cell. 2008 Apr 25;30(2):179-89
pubmed: 18439897
Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1476
pubmed: 29693319
Clin Cancer Res. 2021 Feb 1;27(3):799-806
pubmed: 33172896
Cell. 2005 Aug 12;122(3):365-78
pubmed: 16096057
PLoS One. 2013;8(1):e53803
pubmed: 23326511
Mol Cancer. 2019 Dec 23;18(1):188
pubmed: 31870368
Oncol Lett. 2017 Nov;14(5):5393-5399
pubmed: 29113173
Mol Cell. 2003 Jul;12(1):5-14
pubmed: 12887888
Cancer Res. 2014 Feb 15;74(4):1105-15
pubmed: 24371231
EMBO J. 1995 Jul 17;14(14):3540-51
pubmed: 7543047
Mol Cell. 2004 Nov 19;16(4):597-607
pubmed: 15546619
Nat Genet. 2008 Dec;40(12):1413-5
pubmed: 18978789
PLoS Genet. 2016 Apr 19;12(4):e1005895
pubmed: 27093186
Mol Cancer. 2017 May 11;16(1):90
pubmed: 28490334
Cancer Lett. 2017 Jun 28;396:53-65
pubmed: 28315432
Cell Rep. 2012 Feb 23;1(2):110-7
pubmed: 22545246
Nat Struct Mol Biol. 2007 Mar;14(3):185-93
pubmed: 17310252
Nat Struct Mol Biol. 2012 Jan 15;19(2):220-8
pubmed: 22245967
Biochem Biophys Res Commun. 2016 Mar 18;471(4):459-65
pubmed: 26898802
J Clin Invest. 2019 Feb 1;129(2):676-693
pubmed: 30481162
Nat Struct Mol Biol. 2013 Jan;20(1):36-45
pubmed: 23241926
Nat Commun. 2014 Aug 05;5:4581
pubmed: 25091051
Cells. 2021 Apr 09;10(4):
pubmed: 33918758
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474
pubmed: 32303702
Nat Cell Biol. 2017 Nov;19(11):1358-1370
pubmed: 29058718
EBioMedicine. 2018 Dec;38:113-126
pubmed: 30429088
Dev Cell. 2009 Apr;16(4):528-38
pubmed: 19386262
Theranostics. 2019 Jul 9;9(16):4779-4794
pubmed: 31367257
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Treat Rev. 2016 Apr;45:87-96
pubmed: 26995633
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Blood. 2015 Mar 5;125(10):1562-5
pubmed: 25593337
Nature. 2008 Nov 27;456(7221):470-6
pubmed: 18978772
Mol Cell. 2013 Apr 11;50(1):56-66
pubmed: 23478443
Genes Dev. 1992 May;6(5):837-47
pubmed: 1577277
Mol Cell. 2015 Oct 1;60(1):105-17
pubmed: 26431027
Mol Cell. 2005 Dec 22;20(6):881-90
pubmed: 16364913
Cancer Lett. 2021 Mar 31;501:83-104
pubmed: 33309781
Genes (Basel). 2017 Oct 05;8(10):
pubmed: 28981467
Cell Rep. 2017 Dec 19;21(12):3406-3413
pubmed: 29262322
Exp Cell Res. 2020 Apr 15;389(2):111884
pubmed: 32014444
Nucleic Acids Res. 2014 Apr;42(6):4019-30
pubmed: 24442672
Lab Invest. 2018 Dec;98(12):1562-1574
pubmed: 30181552
Cancer Cell. 2014 Sep 8;26(3):374-389
pubmed: 25203323
Nucleic Acids Res. 2015 Apr 30;43(8):4202-18
pubmed: 25845590
Cancer Res. 2017 Mar 1;77(5):1168-1178
pubmed: 28082404
Mol Cell. 2013 Apr 25;50(2):223-35
pubmed: 23562324
Oncogenesis. 2018 Jan 24;7(1):9
pubmed: 29362363
Mol Cell. 2007 Jun 22;26(6):867-81
pubmed: 17588520
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158
Theranostics. 2020 Feb 10;10(8):3451-3473
pubmed: 32206101